Suppliers and packagers for generic pharmaceutical drug: eszopiclone

eszopiclone

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	A-S Medication Solutions	50090-3514-0	30 TABLET, FILM COATED in 1 BOTTLE (50090-3514-0)	2016-09-15
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	A-S Medication Solutions	50090-7744-0	30 TABLET, FILM COATED in 1 BOTTLE (50090-7744-0)	2016-09-15
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	A-S Medication Solutions	50090-7745-0	30 TABLET, FILM COATED in 1 BOTTLE (50090-7745-0)	2016-09-15
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	A-S Medication Solutions	50090-7746-0	30 TABLET, FILM COATED in 1 BOTTLE (50090-7746-0)	2016-09-15
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	Aurobindo Pharma Limited	65862-967-01	100 TABLET, FILM COATED in 1 BOTTLE (65862-967-01)	2016-09-15
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	Aurobindo Pharma Limited	65862-967-30	30 TABLET, FILM COATED in 1 BOTTLE (65862-967-30)	2016-09-15
Aurobindo Pharma	ESZOPICLONE	eszopiclone	TABLET;ORAL	208451	ANDA	Aurobindo Pharma Limited	65862-968-01	100 TABLET, FILM COATED in 1 BOTTLE (65862-968-01)	2016-09-15

ESZOPICLONE API SUPPLIERS

Last updated: February 19, 2026

This report analyzes key suppliers for eszopiclone, the active pharmaceutical ingredient (API) in Lunesta, a widely prescribed nonbenzodiazepine hypnotic used for treating insomnia. The analysis focuses on manufacturers with established production capabilities, regulatory compliance, and a significant market presence. Identifying reliable API sources is critical for generic drug manufacturers aiming to enter or expand within the eszopiclone market, directly impacting cost of goods sold and supply chain stability.

WHAT ARE THE PRIMARY API SUPPLIERS FOR ESZOPICLONE?

The global market for eszopiclone API is primarily served by a concentrated group of manufacturers, predominantly located in India and China. These suppliers have developed expertise in producing complex chiral molecules like eszopiclone, which requires stringent quality control and adherence to Good Manufacturing Practices (GMP). Key players include companies with strong regulatory track records and significant manufacturing capacities.

• Divi’s Laboratories: An India-based company recognized for its large-scale API production. Divi’s has a broad portfolio of APIs and a history of supplying major pharmaceutical markets. Their manufacturing facilities are approved by regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Sun Pharmaceutical Industries Ltd.: Another prominent Indian pharmaceutical giant. Sun Pharma is a vertically integrated company involved in API manufacturing and finished dosage forms. Their API division is a significant contributor to their global supply chain.

• Laurus Labs: An Indian API manufacturer with a strong focus on complex chemistry and a growing international presence. Laurus Labs is known for its robust R&D capabilities and its ability to scale up production efficiently.

• Zydus Lifesciences (formerly Cadila Healthcare): An integrated Indian pharmaceutical company with significant API manufacturing operations. Zydus has a global footprint and a diverse product pipeline, including APIs for various therapeutic areas.

• ASL, Inc.: A U.S.-based pharmaceutical ingredient supplier that may source and distribute eszopiclone API, often through partnerships with overseas manufacturers, ensuring compliance with U.S. regulatory standards.

• Various Chinese Manufacturers: Several Chinese API producers are active in the eszopiclone market. These companies often compete on price while maintaining necessary quality certifications. Specific company names can fluctuate due to market dynamics and regulatory shifts. Examples of companies that have historically been involved in API supply include those with GMP certifications from relevant authorities.

HOW DO SUPPLIER CAPABILITIES VARY FOR ESZOPICLONE API PRODUCTION?

Supplier capabilities for eszopiclone API production vary based on several factors, including manufacturing scale, technological expertise, regulatory compliance, and cost-efficiency. Eszopiclone, being the S-enantiomer of zopiclone, requires stereoselective synthesis, demanding advanced chiral chemistry capabilities.

• Manufacturing Scale and Capacity: Large-scale manufacturers like Divi’s Laboratories and Sun Pharma can produce multi-ton quantities of eszopiclone API annually, catering to the needs of major generic drug producers. Smaller or specialized manufacturers may have more limited capacities, focusing on niche markets or specific clients.

• Technological Expertise: Companies with advanced R&D departments can develop more efficient and cost-effective synthesis routes. This includes expertise in chiral resolution or asymmetric synthesis, which are crucial for producing high-purity eszopiclone. Laurus Labs, for instance, is noted for its investment in process chemistry innovation.

• Regulatory Compliance: All API suppliers must adhere to stringent GMP standards. Facilities are regularly inspected by regulatory bodies such as the FDA, EMA, and national agencies. Suppliers with a history of successful inspections and a Drug Master File (DMF) filed with the FDA are generally preferred by Western pharmaceutical companies. Divi’s Laboratories and Sun Pharma consistently maintain high regulatory compliance standards.

• Quality Control and Assurance: Robust quality control (QC) and quality assurance (QA) systems are essential to ensure the purity, potency, and consistency of the eszopiclone API. This includes analytical testing for impurities, enantiomeric excess, and physical characteristics. Suppliers with ISO certifications and comprehensive QC laboratories offer a higher degree of assurance.

• Supply Chain Integration: Some suppliers are vertically integrated, manufacturing key intermediates themselves, which can lead to greater control over the supply chain and potentially lower costs. Others may rely on third-party suppliers for raw materials, increasing supply chain complexity and risk.

• Cost Structure: Manufacturers in India and China often benefit from lower labor and operational costs, enabling them to offer competitive pricing for eszopiclone API. However, price alone should not be the sole determinant; quality and reliability are paramount.

WHAT ARE THE KEY REGULATORY CONSIDERATIONS FOR ESZOPICLONE API SUPPLIERS?

Regulatory compliance is a critical barrier to entry and a primary differentiator for eszopiclone API suppliers. Pharmaceutical companies sourcing API must ensure their suppliers meet the rigorous standards set by health authorities worldwide.

• Good Manufacturing Practices (GMP): All eszopiclone API must be manufactured in facilities compliant with cGMP. This includes guidelines outlined by the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and other international bodies. Compliance involves rigorous documentation, process validation, facility maintenance, and personnel training.

• Drug Master Files (DMFs): Suppliers typically file DMFs with regulatory agencies like the FDA. A DMF contains detailed information about the manufacturing process, facility, quality control, and stability of the API. Pharmaceutical companies reference these DMFs in their own Abbreviated New Drug Applications (ANDAs) for generic eszopiclone products. The completeness and acceptance of a DMF directly impact the speed of regulatory approval for the finished drug product.

• Inspections and Audits: API manufacturing sites are subject to periodic inspections by regulatory authorities. Pharmaceutical companies also conduct their own audits of potential and existing suppliers to verify compliance and assess operational quality. Suppliers with a history of successful FDA and EMA inspections are highly valued. For example, facilities that have passed recent FDA inspections for other APIs often demonstrate a baseline of compliance applicable to eszopiclone.

• Impurity Profiling and Control: Regulatory agencies require thorough characterization and control of impurities in APIs. For eszopiclone, this includes monitoring for related substances, residual solvents, and genotoxic impurities. Suppliers must demonstrate that their manufacturing process consistently produces API within established impurity limits. Specifications for impurities are often guided by ICH guidelines (e.g., ICH Q3A(R2) for impurities in new drug substances).

• Enantiomeric Purity: As eszopiclone is the S-enantiomer of zopiclone, ensuring high enantiomeric purity is a critical regulatory requirement. The API must have a very low level of the R-enantiomer (dextrozopiclone), which could have different pharmacological or toxicological profiles. Specifications for enantiomeric excess (e.e.) are stringent, typically requiring e.e. > 99%.

• Stability Testing: Suppliers must provide comprehensive stability data for their eszopiclone API, demonstrating its shelf-life under various storage conditions. This data is essential for determining the expiration date of the API and its impact on the finished drug product's shelf-life.

• Country of Origin and Supply Chain Transparency: Regulatory bodies are increasingly scrutinizing supply chains for transparency and security. Suppliers must provide clear information about their sourcing of raw materials and intermediates, and ensure that any third-party manufacturers involved also meet regulatory standards.

WHAT IS THE MARKET DYNAMICS AND COMPETITIVE LANDSCAPE FOR ESZOPICLONE API?

The market for eszopiclone API is largely driven by the demand for generic Lunesta and other branded eszopiclone products. The competitive landscape is characterized by price competition, quality differentiation, and the ability to navigate complex regulatory pathways.

• Patent Expirations and Generic Entry: The patent expiration of Lunesta (eszopiclone) by Sun Pharma's subsidiary, Jazz Pharmaceuticals, opened the door for generic competition. This led to increased demand for eszopiclone API from generic drug manufacturers seeking to launch their own formulations. The first generic version entered the market in 2014.

• Pricing Pressures: With multiple generic manufacturers competing, there is significant downward pressure on the pricing of finished dosage forms, which directly impacts the price API suppliers can command. Manufacturers with efficient production processes and economies of scale are better positioned to remain competitive. For instance, Indian API manufacturers have historically offered competitive pricing.

• Key API Suppliers' Market Share: Divi’s Laboratories and Sun Pharma are considered major suppliers due to their established infrastructure and regulatory approvals. Laurus Labs and Zydus Lifesciences are also significant contributors. The exact market share can be difficult to quantify precisely due to private contractual agreements.

• Geographic Concentration: The majority of high-volume eszopiclone API production is concentrated in India and China, reflecting the cost advantages and established pharmaceutical manufacturing ecosystems in these regions.

• Impact of Regulatory Scrutiny: Increased regulatory scrutiny, particularly from the FDA regarding quality and data integrity, can lead to temporary supply disruptions or disqualification of suppliers. This reinforces the importance of partnering with suppliers who have a proven track record of consistent compliance.

• Emerging Market Demand: While developed markets remain the primary consumers, there is growing demand for eszopiclone in emerging markets as healthcare access and prescription practices evolve.

• Strategic Partnerships: Pharmaceutical companies often form long-term strategic partnerships with API suppliers to ensure a stable and cost-effective supply. These partnerships can involve co-development of manufacturing processes or commitments to specific volumes.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES FOR ESZOPICLONE API?

The eszopiclone API supply chain, like many in the pharmaceutical industry, faces several potential risks. Proactive mitigation strategies are essential for ensuring uninterrupted production of finished drug products.

• Regulatory Non-Compliance: A supplier's failure to meet GMP standards or a warning letter from a regulatory agency can halt production and necessitate a rapid switch to an alternative source, which is costly and time-consuming.

  • Mitigation: Conduct thorough due diligence on potential suppliers, including reviewing regulatory inspection histories and financial stability. Maintain relationships with multiple qualified suppliers.

• Geopolitical Instability and Trade Policies: Tensions between major trading nations or disruptions in key manufacturing regions can impact raw material availability and the movement of goods.

  • Mitigation: Diversify sourcing across different geographic regions where feasible. Monitor global political and trade developments closely.

• Quality Issues and Recalls: Manufacturing defects, contamination, or out-of-specification batches can lead to API recalls, impacting both the supplier and downstream drug manufacturers.

  • Mitigation: Implement robust incoming material testing protocols. Conduct regular on-site audits of supplier quality systems. Require comprehensive Certificates of Analysis (CoAs) for every batch.

• Raw Material Shortages: Dependence on specific raw materials or intermediates that are subject to their own supply chain vulnerabilities can affect eszopiclone production.

  • Mitigation: Understand the upstream supply chain of API manufacturers. Encourage suppliers to qualify multiple sources for critical raw materials.

• Intellectual Property Disputes: While patents on the primary molecule may have expired, there can be disputes over manufacturing processes or polymorphs.

  • Mitigation: Ensure that the chosen manufacturing process does not infringe on existing process patents. Seek legal counsel for IP review.

• Logistical Disruptions: Shipping delays, port congestion, or unforeseen events like pandemics can disrupt the timely delivery of API.

  • Mitigation: Utilize multiple shipping routes and carriers. Maintain adequate buffer stock of API where feasible and storage conditions permit.

• Price Volatility: Fluctuations in the cost of raw materials, energy, or labor can lead to unexpected price increases for the API.

  • Mitigation: Negotiate long-term supply agreements with price adjustment clauses tied to a clear index. Explore opportunities for hedging against raw material price volatility.

Key Takeaways

• The eszopiclone API market is dominated by a few large-scale manufacturers primarily located in India and China, including Divi’s Laboratories, Sun Pharmaceutical Industries, Laurus Labs, and Zydus Lifesciences.
• Regulatory compliance, particularly adherence to cGMP and successful DMF filings with agencies like the FDA and EMA, is paramount for API suppliers.
• Key capabilities differentiating suppliers include manufacturing scale, technological expertise in chiral synthesis, robust quality control systems, and a history of regulatory approvals.
• The competitive landscape is driven by generic competition, leading to price pressures. Suppliers with efficient processes and strong regulatory standing are better positioned.
• Supply chain risks include regulatory non-compliance, geopolitical instability, quality issues, raw material shortages, and logistical disruptions, requiring diversification, rigorous audits, and robust inventory management.

FAQs

1. Which regulatory bodies are most critical for eszopiclone API suppliers to be approved by? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the most critical for suppliers aiming to serve major Western markets. National regulatory bodies in other significant markets (e.g., Health Canada, Australia's TGA) are also important.

2. What is the typical enantiomeric purity required for eszopiclone API? Eszopiclone API must demonstrate very high enantiomeric purity, typically requiring an enantiomeric excess (e.e.) of greater than 99% of the S-enantiomer to ensure efficacy and safety.

3. How does the existence of multiple generic Lunesta manufacturers affect API suppliers? The presence of numerous generic manufacturers intensifies competition, leading to downward pressure on API prices and requiring suppliers to focus on cost-efficiency and high-volume production to remain competitive.

4. Are there any significant API suppliers based outside of India and China? While the majority of high-volume production originates from India and China, some companies in North America and Europe may be involved in specialized synthesis, niche supply, or as distributors, but typically rely on manufacturing capacity in Asia. ASL, Inc. represents a U.S.-based entity in this space, often facilitating supply through established international networks.

5. What is the role of Drug Master Files (DMFs) in the eszopiclone API supply chain? DMFs are comprehensive documents submitted to regulatory agencies that detail the API manufacturing process, facilities, and controls. Pharmaceutical companies reference these DMFs in their drug applications, making an accepted DMF a critical component for a supplier's market access.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Parts 210 & 211 - Current Good Manufacturing Practice For Finished Pharmaceuticals. U.S. Government Publishing Office. [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. European Commission. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2). [4] Sun Pharma. (n.d.). Company Overview. Retrieved from [Sun Pharma Official Website - Investor Relations/About Us section] (Note: Specific URL for API division details is not publicly linkable without direct navigation to their investor reports or corporate site) [5] Divi’s Laboratories. (n.d.). APIs. Retrieved from [Divi’s Laboratories Official Website - Product Portfolio/APIs section] (Note: Specific URL for eszopiclone details is not publicly linkable without direct navigation to their product catalog) [6] Laurus Labs. (n.d.). APIs. Retrieved from [Laurus Labs Official Website - Product Portfolio/APIs section] (Note: Specific URL for eszopiclone details is not publicly linkable without direct navigation to their product catalog) [7] Zydus Lifesciences. (n.d.). API Manufacturing. Retrieved from [Zydus Lifesciences Official Website - Business Verticals/API section] (Note: Specific URL for eszopiclone details is not publicly linkable without direct navigation to their product catalog) [8] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Official Website - Drug Master Files Information] (Note: Specific URL for DMF database search is not provided as it's an interactive tool) [9] Jazz Pharmaceuticals plc. (n.d.). Lunesta (eszopiclone) Product Information. Retrieved from [Jazz Pharmaceuticals Official Website/Product Information section] (Note: Specific URL for historical patent information and product details is not directly provided, but is generally available through pharmaceutical databases and company archives)